Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00929968 | Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis | PHASE2 | COMPLETED | 35 | — | — | Jun 1, 2009 | - | Dec 19, 2020 | 2 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Placebo to VAK694 | PLACEBO_COMPARATOR | - |
| VAK694 | EXPERIMENTAL | - |
| Fluticasone propionate | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | BIOLOGICAL | - |
| VAK694 | BIOLOGICAL | - |
| Fluticasone | DRUG | - |
Inclusion Criteria: * Male and female subjects between ages of 18 to 60 in good health * History of atopy for at least 2 years and positive skin prick test to ragweed allergen Exclusion criteria: * History of asthma treated with corticosteroids * Smokers with a smoking history of \> 10 pack/years...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |